Lecanemab in patients with early Alzheimer's disease
Lecanemab 10 mg/kg biweekly showed dose-dependent reductions in brain amyloid, improved plasma biomarkers, and slowed cognitive decline in Alzheimer's patients. Treatment differences vs placebo were maintained over 24 months, with amyloid PET and plasma biomarkers indicating sustained effects. The study supports lecanemab's potential for disease modification in early AD stages.
Related Clinical Trials
Reference News
Lecanemab treatment showed significant reduction in brain amyloid and slowed clinical decline in Alzheimer's disease patients. A total of 856 subjects were randomized, with lecanemab demonstrating dose-dependent amyloid reduction. Plasma biomarkers improved, correlating with slower disease progression. Discontinuation led to amyloid reaccumulation, but treatment effects persisted during the gap period.
Lecanemab 10 mg/kg biweekly showed dose-dependent reductions in brain amyloid, improved plasma biomarkers, and slowed cognitive decline in Alzheimer's patients. Treatment differences vs placebo were maintained over 24 months, with amyloid PET and plasma biomarkers indicating sustained effects. The study supports lecanemab's potential for disease modification in early AD stages.